Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis

Haematologica

Volumn 93, Issue 3, 2008, Pages

  Mignot, Aude ^a,e   Bridoux, Frank ^a,e   Thierry, Antoine ^a,e   Varnous, Shaida ^b   Pujo, Myriam ^c   Delcourt, Annick ^b   Gombert, Jean Marc ^a,e   Goujon, Jean Michel ^a,e   Favreau, Fréderic ^a   Touchard, Guy ^a,e   Herpin, Daniel ^a   Jaccard, Arnaud ^d,e,f  

^a UNIVERSITÉ DE POITIERS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Department of Nephrology ^*  (France)

^d UNIVERSITY OF LIMOGES   (France)

^e Ctr de Ref des Amyloses Primitives et des Autres Maladies de Depots d'Immunoglobuline Monoclonale

^f LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

AL amyloidosis; Cardiac transplantation; Dexamethasone; Melphalan

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; FOSCARNET; MELPHALAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; ELECTROCARDIOGRAM; ELECTRON MICROSCOPY; FOLLOW UP; GRAFT REJECTION; HEART AMYLOIDOSIS; HEART FAILURE; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY TEST; MALE; MONOTHERAPY; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

AMYLOIDOSIS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MELPHALAN; MIDDLE AGED; NEPHROTIC SYNDROME; PARAPROTEINEMIAS; PERIPHERAL NERVOUS SYSTEM DISEASES; RECURRENCE;

EID: 40849127230     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12108     Document Type: Article

References (18)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Kyle RA, Morie AG, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999;93:1062-6.
3. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60.
4. Conner R, Hosenpud JD, Norman DJ, Pantely GA, Cobanoglu A, Starr A. Heart transplantation for cardiac amyloidosis : successful one-year outcome despite recurrence of the disease. J Heart Transplant 1988;7:165-72.
5. Valentine HA, Billingham ME. Recurrence of amyloid in a cardiac allograft four months after transplantation. J Heart Transplant 1989;8:337-41.
6. Hosenpud JD, DeMarco T, Frazier Oh, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation 1991;84:338-43.
7. Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR. Long term results of heart transplantation in patients with amyloid heart disease. Heart 2001;85:202-207.
8. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: The United Kingdom Experience. J Heart Lung Transplant 2004;23:42-1153.
9. Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005;24:1763-5.
10. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006;107:1227-9.
11. Novak L, Cook WJ, Herrera GA, Sanders PW. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant 2004;19:3050-3.
12. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82.
13. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
14. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103: 2936-8.
15. Jaccard A, Moreau P, Leblond V, et al. Autologous stem cell transplantation versus oral melphalan plus high-dose dexamethasone in patients with AL (primary) amyloidosis: results of a French randomized trial. N Engl J Med 2007, in press.
16. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natiruretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8.
17. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005;79:319-28.
18. Guidelines Working Group of UK Myeloma Forum; British Committee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004;125:681-700.